Abbvie Inc.

University of Notre Dame Du Lac

The General Hospital Corporation

Memorial Sloan Kettering Cancer Center

East Carolina University

Abbvie Manufacturing Management Unlimited Company

Cheng Ji

George A Doherty

Marvin J Miller

Thomas Dale Penning

Andrew J Souers

Xilu Wang

Michael D Wendt

Zhi-Fu Tao

Milan Bruncko

Aaron R Kunzer

Xiaohong Song

Andrew S Judd

Derek Shieh Tan

Chunqiu Lai

Laurence G Rahme

Erwin R Boghaert

Mark Anderson

Anthony Mastracchio

Andrew C Phillips

Patricia Miller

Everett C Pesci

Debarshi Pratihar

James P Coleman

Regina M Reilly

Indrajeet Sharma

The present disclosure provides c-Met antibody drug conjugates (ADCs), including compositions and methods of using such ADCs.

Anti-c-Met antibody drug conjugates

A compound is provided, comprising: an Fe(III)-binding or an Fe(III)-bound siderophore; one or more optional linker covalently bound to the siderophore; a drug; and an Fe(III) to Fe(II) reduction triggered linker bound to the drug and the linker or, if no linker is present, then bound to the drug and the siderophore. Compositions and methods including the compound are also provided.

Reduction-triggered antibacterial sideromycins

Provided herein are compounds of Formula (I) and pharmaceuticals acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, and prodrugs thereof. Also provided are pharmaceutical compositions, kits, and methods involving the inventive compounds for the treatment and/or of an infectious disease (e.g., bacterial infection (e.g.,infection). 

Anthranilyl-adenosinemonosulfamate analogs and uses thereof

The present disclosure provides for compounds of formula (I) wherein A, A, A, A, A, A, A, R, R, R, R, R, R, R, R, R, R, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of formula (I).

Macrocyclic MCL-1 inhibitors and methods of use

An artificial tris-catecolate siderophore with a tripodal backbone and its conjugates with ampicillin and amoxicillin were synthesized. Both conjugates exhibited significantly enhanced in vitro antibacterial activities against Gram-negative species compared to the parent drugs, especially against. The conjugates appear to be assimilated by an induced bacterial iron transport process as their activities were inversely related to iron concentration. The easily synthesized tris-catecolate siderophores can be used with a variety of drugs as conjugates to target antibiotic-resistant Gram-negative bacteria.

Anti-bacterial siderophore-aminopenicillin conjugates

Growing community of inventors

Buffalo Grove, IL, United States of America

Cheng Ji